Novartis provides update on Phase III GCAptAIN study of Cosentyx\u00ae in giant cell arteritis (GCA)

• click to rate

  Posted by Two Blokes Jul 3 - Filed in Stock - 4 views
  
  Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx\u00ae (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).